Posted by admin on Aug 8th, 2022
NuVasive (NASDAQ:NUVA – Get Rating) had its price target trimmed by Piper Sandler from $80.00 to $60.00 in a report released on Thursday, Marketbeat reports. The brokerage currently has an overweight rating on the medical device company’s stock.
Several other research firms also recently issued reports on NUVA. Truist Financial lowered their price objective on NuVasive to $63.00 in a research note on Friday, July 22nd. Morgan Stanley reduced their target price on NuVasive from $62.00 to $54.00 and set an equal weight rating on the stock in a report on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, NuVasive currently has an average rating of Hold and a consensus target price of $61.75.
NuVasive stock opened at $51.47 on Thursday. The business has a 50 day moving average of $51.17 and a 200-day moving average of $52.80. NuVasive has a 1 year low of $45.45 and a 1 year high of $64.43. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.17 and a quick ratio of 1.88. The company has a market capitalization of $2.68 billion, a P/E ratio of -64.34, a P/E/G ratio of 2.01 and a beta of 1.14.
A number of large investors have recently modified their holdings of the company. Strs Ohio purchased a new stake in NuVasive in the 2nd quarter valued at $73,000. Point72 Hong Kong Ltd raised its position in NuVasive by 28.3% in the 1st quarter. Point72 Hong Kong Ltd now owns 1,347 shares of the medical device company’s stock valued at $76,000 after buying an additional 297 shares during the last quarter. Captrust Financial Advisors raised its position in NuVasive by 85.7% in the 1st quarter. Captrust Financial Advisors now owns 2,108 shares of the medical device company’s stock valued at $120,000 after buying an additional 973 shares during the last quarter. PNC Financial Services Group Inc. raised its position in NuVasive by 76.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,175 shares of the medical device company’s stock valued at $123,000 after buying an additional 942 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in NuVasive in the 1st quarter valued at $189,000.
NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.
JPMorgan Chase & Co. Trims Qorvo (NASDAQ:QRVO) Target Price to $125.00
Piper Sandler Cuts Qorvo (NASDAQ:QRVO) Price Target to $115.00